Morgan Stanley upgraded Veeva Systems to Equal-weight after the stock fell 45% from its peak to a 10-year low, citing better-understood competitive risks and potentially oversold sentiment. The decline followed the loss of four of the top 10 pharmaceutical clients in its customer relationship management business and broader AI disruption concerns.

The firm cut its price target to $205 from $222, reflecting lower sector valuation multiples. Veeva's enterprise value to free cash flow ratio has dropped to decade lows, with the company holding $6.6 billion in cash, no debt, and generating $1.4 billion in annual free cash flow. A $2 billion share buyback authorized in January provides additional support.

Morgan Stanley expects Veeva to slightly beat fourth-quarter earnings estimates, with fiscal 2027 guidance broadly in line with expectations. The debate has shifted from earlier confidence that Salesforce could not gain share in life sciences to concerns about Veeva's ability to meet 2030 targets. AI remains a key swing factor, with new large language model tools for clinical trial processes raising questions about the durability of Veeva's moat, particularly for legacy products like electronic trial master file software.